Investigating the role of RNA modifications in Duchenne muscular dystrophy
N6-Methyladenosine Methylome in Duchenne Muscular Dystrophy
This study is looking at how a special change in RNA, called m6A, affects muscle growth and healing in boys with Duchenne muscular dystrophy (DMD), with the hope of finding new ways to help treat this challenging condition.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Albany NIH-funded |
| Lab location | 1 site (Albany, United States) |
| Project ID | NIH-10802344 on NIH RePORTER |
What this research studies
This research focuses on understanding how a specific chemical modification of RNA, known as N6-methyladenosine (m6A), affects the progression of Duchenne muscular dystrophy (DMD), a severe muscle degenerative disease primarily affecting boys. By studying the mechanisms of m6A regulation, the researchers aim to uncover how it influences muscle cell development and regeneration in DMD. The approach involves analyzing the levels of m6A marks and the proteins that add or remove these modifications during muscle cell differentiation and in the context of DMD. This could lead to new insights into potential therapeutic targets for this devastating condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are boys aged 0-11 years diagnosed with Duchenne muscular dystrophy.
Not a fit: Patients with other forms of muscular dystrophy or those outside the specified age range may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of novel therapies that improve muscle function and quality of life for children with Duchenne muscular dystrophy.
How similar studies have performed: While the specific focus on m6A in DMD is relatively novel, similar approaches in epitranscriptomics have shown promise in other diseases, indicating potential for success.
Where this research is happening
Albany, United States
- State University of New York at Albany — Albany, United States (Active)
Researchers
- Principal investigator: Dey, Bijan K — State University of New York at Albany
- Study coordinator: Dey, Bijan K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.